Austin, May 09, 2025 (Globe Newswire) – Periodontal therapeutic market size and market trends:
According to SNS Insider, Global Periodontal therapeutic market It was estimated at $ 859.13 million in 2023, is on the right track to reach $ 1666.11 million by 2032, extending to CAGR 7.62% during the forecast period. Market development has its roots in increasing cases of chronic periodontal diseases, increasing awareness of dental hygiene and developments in drug delivery technologies.
As the world population ages and urbanizes, the prevalence of gingivitis and chronic periodontitis continues to rise. These gum diseases, often overlooked up to the delayed stages, require prolonged treatment and intervention, promoting demand for systemic antibiotics, anti -inflammatory drugs and drugs to form the host.
Receive a sample of the periodontal therapeutic market@
Only in the US, the market hit $ 246.62 million in 2023 and is expected to reach $ 451.30 million by 2032. High public health costs, early examination programs and refund policies have contributed significantly to early diagnosis and treatment.
Market overview
A major engine on the periodontal therapies market is the increasing incidence of periodontal disease, especially in aging populations. As more people suffer from chronic periodontal diseases, including gingivitis and periodontitis, doctors are increasingly seen for effective drug treatments that can stop growing and improve results. Progresses in the delivery of drugs, including drugs to form host and targeted antibacterial therapies-extend the treatment options and the expansion of the power market. In addition, especially in industrialized areas of the world, the treatment barrier has been reduced by easier access to these medicines through retail and hospital pharmacies.
Significant market component in the United States, awareness campaigns and refund support have led to higher diagnosis rates and rapid interventions. In addition, the cooperation between research institutions and pharmaceutical companies has led to the creation of new drugs intended to target specific bacterial species that cause gum disease. A tendency to preventive dentistry and regular dental visits helps market development, allowing premature diagnosis and treatment of periodontal disease.
Basic periodontal therapeutic companies presented in the report
- 3m Company (Arestin, Peridex)
- Haleon (Parodontax, Biotène)
- Colgate-Palmolive Company (Periogard, Colgate Perioocheck)
- Procter & Gamble (Crest Gum Detoxify, Oral-B Gum Care)
- Glaxosmithkline Plc (Parodontax, Corsodyl)
- Sunstar Americas, Inc. (Gum ParoEx, Gum Technique Deep Clean Todthebrush)
- Dentsply Sirona (Oraqix, Periochip)
- PFIizer Inc. (Doxycycline Hyclate, Azithromycin)
- Johnson & Johnson Services, Inc. (Listerine Gum Therapy, Listerine Advanced Defense Gum Treatment)
- Valeant Pharmaceuticals (now Bausch Health Companies) (Xepi, Periostat)
- Zila, Inc. (Zilactin, Vizilite Plus)
- Bayer AG (Baytril, Perioaid)
- GC Corporation (Gluco-Chax, Cervitec Plus)
- Group Acteon (Satelec Ultrasonic Scalers, Soprolife Detection)
- Mediteam Dental (chlorxid, iodomorphic paste)
- P&G Professional Oral Health (Crest + Oral-B) (Gum Mouthwash Gym, Pro-Health Gum Detoxify)
- Young Innovations, Inc. (Zooby Prophy Paste, Prophy Prophy Agnter)
- Septodont (Septocaine, Cell)
- Nobel Biocare Services AG (Nobelactive implants, Galvosurge)
- Ivoclar Vivadent AG (Cervitec F, Vivastyle Gum Protect)
Scope of the periodontal therapeutic market market
| Trait report | Details |
| Market Size in 2023 | US $ 859.13 million |
| Purchase size by 2032 | 1666.11 million US dollars |
| Cagr | CAGR 7.62% from 2024 to 2032 |
| Base years | 2023 |
| Prediction period | 2024-2032 |
| Historical data | 2020-2022 |
| Basic regional coverage | North America (USA, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe]Germany, France, the United Kingdom, Italy, Spain, the Netherlands, Switzerland, Austria, the rest of Western Europe]Asia -Pacific (China, India, Japan, South Korea, Vietnam, Singapore [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa]Latin America (Brazil, Argentina, Colombia rest of Latin America) |
Department analysis
By type:
In 2023, the category of chronic periodontal disease led to the market with a share of 35.16%, mainly due to the frequency and chronic nature of the disorder, which requires continuous treatment intervention. It is often underestimated to the delayed stages, chronic periodontitis has led to the demand for systemic antibiotics and enzyme suppression drugs to reduce tissue damage and slow down the progression of the disease.
The part of gingivitis is expected to be expanded more during the prediction period. Better oral care practices, more public knowledge of the signs of early stage gum disease and the increasing availability of drugs without a prescription that encourage early treatment before proceeding to more advanced stages represent this expansion. In particular, younger generations find this preventive approach attractive.
Per type of drug:
Doxycycline became the category of drug government in 2023, keeping a market share of 38.19%. It is a preferred treatment medicine as it can reduce the metalloproteinases (MMPs) (MMPs) of periodontal depth and uterine metroproteinases (MMPs) that break down the connective tissue. The twin anti -inflammatory and antibacterial properties of Doxycycline have been integrated into its place as acceptable treatment.
On the other hand, the fastest growing category is expected to be the category of local antimicrobials. They are usually given as gels or fibers directly placed in periodontal pockets, these drugs are more demanding due to their targeted action, reduced systematic adverse reactions and improved patient compliance. The increasing clinical use of targeted treatment techniques and developments in biodegradable delivery technologies leads the category.
Per distribution channel:
Hospital pharmacies maintained the highest position in 2023 with a share of 43.10%, mainly due to the character of the recipe for periodontal therapies and dental professionals working in hospital sites. The main reasons why hospital pharmacies are the first point of contact remain the central supply of sophisticated therapies and the provision of treatment in one place.
Retail pharmacies, however, are in motion and are the fastest growing channel. The rapid expansion of the channel is guided by the increasing need of customers for convenience, as well as the increasing availability of prescription drugs and preventive treatments in retail environments. The further enhancement of the credibility and accessibility of retail stores was the counseling for oral health by chemists and cooperation with the dentist offices.
For a detailed information session with our analysts team, log in with us now@
Splitting the periodontal therapeutic market
Formula
- Gingivitis
- Chronic periodontal disease
- Aggressive periodontal disease
- Others
Per type of drug
- Doxycycline
- Minocycline
- Chlorhexidine
- Metronidazole
- Other types of drugs
Per distribution channel
- Hospital pharmacies
- Retail pharmacies
Regional analysis
North America was the market leader in the worldwide periodontal market market in 2023, representing the 38.07%share, resulting from a rapidly increasing upper population that is sensitive to periodontal disease, established dental infrastructure and dental infrastructure. Driving in this area with high treatment rates, active research programs and continuous oral health investment is the United States.
Asia-Pacific is expected to experience faster growth during the prediction period as a result of extensive access to health care, urbanization and increased oral health awareness. China, India and Japan have seen an upward trend in dental consultations, which are partially driven by governments’ efforts and increasing income. The growing middle class of the area and the evolving dental care ecosystem make a future growth guide.
Recent developments in the periodontal therapeutic market
- September 2024 – Haleon, in collaboration with the National Institute of Health and Care (NIHR), introduced a new dental care to incorporate control for type 2 diabetes as part of dental tests, to detect more than one million non -diagnosed cases.
- February 2024-Colgate-Palmolive introduced the “Periogard Advanced Care” gel for gingivitis, treating the initial gum disease with a stronger type of chlorhexidine for greater tolerance and efficacy.
- January 2024 – The Sunstar Group launched a local system of delivery of periodontal pockets in Japan with its brand, using biopsy -breeds carriers to provide antimicrobial directly in inflammatory positions.
Buy a PDF of a PDF user of periodontal Therapeutics Analysis & Outlook Report 2024-2032@
Table of Contents – Large key points
1. Introduction
2.
3. Research Methodology
4. Analysis of market dynamics effect
5. Statistical knowledge and voltage references
5.1 Impact and prevalence of periodontal diseases (2023)
5.2 Recipe trends for periodontal therapeutic (2023), by region
5.3 Product and Drug Tutorials (2020-2032).
5.4 Sanitary care expenditure for periodontal care, by region (2023)
5.5 Technological Developments in Periodontal Therapeutic (2020-2032)
6. Competitive landscape
7. Periodontal therapeutic market per formula
8. Periodontal therapeutic market per drug type
9. Periodontal therapeutic market per distribution channel
10. Regional Analysis
11. Company profiles
12. Use cases and optimal practices
13. Conclusion
Reports
Oral Care Market Report
Dental Renaissance Purchase Report
Report to buy pet dental health
Digital Dentistry Purchase Report
Market Report of Dental Biomaterials
About us:
SNS Insider is one of the leading market research and counseling organizations dominated in the market research industry worldwide. The purpose of our company is to give customers the knowledge they need to operate in changing conditions. In order to give you the current, precise market data, consumer ideas and opinions, so you can make confidence decisions, we use a variety of techniques, including research, video talks and catering teams around the world.
